# JNJ earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/JNJ) · [Earnings tab](https://www.lopjlb.com/stock/JNJ?tab=earnings)

Updated: 2026-10-05T04:50:34

Quarters analyzed: 8

## Cross-quarter narrative

Across 8 calls for JNJ, management tone moved from +0.00 (2024 Q3) to +0.00 (2026 Q2). Latest guidance stance: vague. Latest desk line: n/a

## Latest CallCard · Q2

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** —
- **2026 Q1:** Johnson & Johnson Q1 2026 delivered 6.4% sales growth, raised full‑year guidance, and highlighted strong early uptake of new launches like ICOTYDE and INLEXZO while noting modest headwinds from tariffs and procedural softness.
- **2025 Q4:** —
- **2025 Q3:** J&J posted 5.4% sales growth, strong oncology and immunology performance, announced Orthopaedics separation and upcoming Ottava FDA filing, while noting STELARA headwinds.
- **2025 Q2:** Johnson & Johnson posted a strong Q2 with 4.6% sales growth, raised full‑year guidance, and highlighted robust oncology and MedTech pipelines despite STELARA biosimilar headwinds.
- **2025 Q1:** J&J posted 4.2% operational sales growth in Q1 2025, highlighted multiple product approvals and a $55 bn U.S. investment plan, while reaffirming its 2025 guidance.
- **2024 Q4:** JNJ 2024 Q4: 7% operational sales growth ex-COVID; 2025 guidance 3% sales growth, ~9% EPS growth despite STELARA biosimilar headwinds; MedTech 6.2% growth; Intra-Cellular acquisition adds CNS pipeline.
- **2024 Q3:** —

## Theme arcs

- **Management tone** (stable): Δ mgmt=+0.00

## Fear persistence

- **regulatory risk** [recurring]: 2025 Q1, 2025 Q3, 2026 Q1
- **competitive pressure** [resolved]: 2025 Q1
- **litigation risk** [resolved]: 2025 Q1
- **tariff/transfer pricing risk** [resolved]: 2025 Q1
- **supply chain risk** [resolved]: 2025 Q1
- **market adoption risk** [resolved]: 2025 Q1
- **economic uncertainty** [resolved]: 2025 Q1
- **currency risk** [resolved]: 2025 Q1
- **biosimilar competition** [resolved]: 2025 Q2
- **regulatory redesign** [resolved]: 2025 Q2

## Guidance path

2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:raised → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:raised → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/JNJ`